The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. Opdivo is part of a class of drugs called PD-1 inhibitors,
Most of the recalls are contamination or allergen-based. While 2025 is near, there are still callbacks to be aware of. Here is a list of December recalls according to the FDA. FDA
The U.S. Food and Drug Administration (FDA) recently finalized its long-awaited rule redefining the use of the term “healthy” on food packaging.
On December 27, 2024, the U.S. Food and Drug Administration (FDA) published a final rule updating the criteria regarding when foods may be
BLAIR COUNTY, Pa (WJAC) — The U.S. Food and Drug Administration (FDA) has issued a temporary recall of the latest Gardners Candies' specialty candy bars. According to the announcement, the Blair County-based candy company is recalling its new "Cappuccino Meltaway" bars due to an undeclared tree nut allergen and packaging issue.
The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes.
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
The U.S. Food and Drug Administration redefined its parameters for “healthy” food for the first time in 30 years.
Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two new clinical trials.
In early December, the Supreme Court heard oral argument in Food and Drug Administration v. Wages and White Lion Investments, a challenge to the FDA's
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over.
Verastem Oncology said its treatment for recurrent low-grade serous ovarian cancer has been given priority review by the Food and Drug Administration. The new drug application for the treatment in adults combines two drugs, avutometinib and defactinib.